Lupin surges on launching Rufinamide Oral Suspension in United States
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lupin is currently trading at Rs. 856.30, up by 4.40 points or 0.52% from its previous closing of Rs. 851.90 on the BSE.
The scrip opened at Rs. 850.05 and has touched a high and low of Rs. 865.55 and Rs. 847.85 respectively. So far 136244 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 885.00 on 21-Jun-2023 and a 52 week low of Rs. 602.80 on 04-Aug-2022.
Last one week high and low of the scrip stood at Rs. 885.00 and Rs. 821.00 respectively. The current market cap of the company is Rs. 38968.50 crore.
The promoters holding in the company stood at 47.08%, while Institutions and Non-Institutions held 42.52% and 10.40% respectively.
Lupin has launched Rufinamide Oral Suspension, 40 mg/mL to market a generic equivalent of Banzel Oral Suspension, 40 mg/mL of Eisai Inc. Rufinamide Oral Suspension (RLD Banzel) had estimated annual sales of $72 million in the U.S.
Earlier, the company had launched Thiamine Hydrochloride Injection USP, 200 mg/2 mL (100 mg/mL) Multiple-dose Vials, after Lupin’s alliance partner Caplin Steriles (Caplin) received an approval for its ANDA from the United States Food and Drug Administration (USFDA).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
.jpg)
